Education
About Us
Working with TipRanks
Follow Us
Medesis Pharma SA (FR:ALMDP)
:ALMDP
ALMDP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $2.00
Previous CloseN/A
Volume2.08K
Average Volume (3M)0.00
Market Cap
$1.76M
Enterprise ValueN/A
Total Cash (Recent Filing)$41.79K
Total Debt (Recent Filing)€1.20M
Price to Earnings (P/E)―
Beta0.58
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,061,082
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Medesis Pharma SA News
PremiumCompany Announcements
Promising Alzheimer’s Treatment Advances in TrialALMDP FAQ
What was Medesis Pharma SA’s price range in the past 12 months?
Medesis Pharma SA lowest stock price was $0.30 and its highest was $2.00 in the past 12 months.
What is Medesis Pharma SA’s market cap?
Medesis Pharma SA’s market cap is $1.76M.
When is Medesis Pharma SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medesis Pharma SA’s earnings last quarter?
Currently, no data Available
Is Medesis Pharma SA overvalued?
According to Wall Street analysts Medesis Pharma SA’s price is currently Overvalued.
Does Medesis Pharma SA pay dividends?
Medesis Pharma SA does not currently pay dividends.
What is Medesis Pharma SA’s EPS estimate?
Medesis Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medesis Pharma SA have?
Medesis Pharma SA has 5,061,082 shares outstanding.
What happened to Medesis Pharma SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Medesis Pharma SA?
Currently, no hedge funds are holding shares in FR:ALMDP
Company Description
Medesis Pharma SA
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.